Provisions of the One Big Beautiful Bill Act excluded or delayed consideration of several of Medicare’s most expensive drugs from price negotiation.
Cancer treatment drugs. Ryan Adams/Flickr
|Updated:
Pharmaceutical companies can continue to charge the federal government—and Medicare beneficiaries—full price for a handful of drugs that might have seen price reductions as soon as next year.
That’s because Congress changed the law to outright exempt or delay consideration of more than 300 medications for the Medicare Drug Price Negotiation Program.
Lawrence Wilson covers politics for The Epoch Times.
